| Id |
Subject |
Object |
Predicate |
Lexical cue |
| p1_all0 |
391-408 |
Intervention |
denotes |
Xyloketal B (XKB) |
| p2_i0 |
391-408 |
Pharmacological |
denotes |
Xyloketal B (XKB) |
| p1_all1 |
709-712 |
Intervention |
denotes |
XKB |
| p1_all2 |
773-776 |
Intervention |
denotes |
XKB |
| p2_i1 |
773-776 |
Pharmacological |
denotes |
XKB |
| p1_all3 |
811-865 |
Population |
denotes |
rat cytochrome P450 3a (Cyp3a) subfamily members using |
| p1_all4 |
866-875 |
Intervention |
denotes |
midazolam |
| p2_i2 |
866-875 |
Pharmacological |
denotes |
midazolam |
| p1_all5 |
894-901 |
Intervention |
denotes |
DDI-CPI |
| p1_all6 |
1256-1300 |
Outcome |
denotes |
activity and expression of rat hepatic Cyp3a |
| p2_o7 |
1256-1300 |
Physical |
denotes |
activity and expression of rat hepatic Cyp3a |
| p1_all7 |
1348-1351 |
Intervention |
denotes |
XKB |
| p2_i3 |
1348-1351 |
Pharmacological |
denotes |
XKB |
| p1_all8 |
1394-1467 |
Outcome |
denotes |
Rat plasma concentrations of midazolam and its metabolite 1′-OH-midazolam |
| p2_o8 |
1394-1467 |
Physical |
denotes |
Rat plasma concentrations of midazolam and its metabolite 1′-OH-midazolam |
| p2_i4 |
1423-1432 |
Pharmacological |
denotes |
midazolam |
| p1_all9 |
1737-1740 |
Intervention |
denotes |
XKB |
| p2_i5 |
1737-1740 |
Pharmacological |
denotes |
XKB |
| p1_all10 |
1915-1918 |
Intervention |
denotes |
XKB |
| p2_i6 |
1915-1918 |
Pharmacological |
denotes |
XKB |
| p1_all11 |
1978-2043 |
Outcome |
denotes |
area under the plasma concentration-time curve (AUC) of midazolam |
| p2_o11 |
1978-2043 |
Physical |
denotes |
area under the plasma concentration-time curve (AUC) of midazolam |
| p2_i7 |
2034-2043 |
Pharmacological |
denotes |
midazolam |
| p1_all12 |
2080-2129 |
Outcome |
denotes |
plasma clearance and AUC ratio of 1′-OH-midazolam |
| p2_o11 |
2080-2129 |
Physical |
denotes |
plasma clearance and AUC ratio of 1′-OH-midazolam |
| p2_i8 |
2135-2144 |
Pharmacological |
denotes |
midazolam |
| p1_all13 |
2187-2190 |
Intervention |
denotes |
XKB |
| p2_i9 |
2187-2190 |
Pharmacological |
denotes |
XKB |
| p1_all14 |
2223-2263 |
Outcome |
denotes |
activity and expression of hepatic Cyp3a |
| p2_o12 |
2223-2263 |
Physical |
denotes |
activity and expression of hepatic Cyp3a |
| p1_all15 |
2311-2314 |
Intervention |
denotes |
XKB |
| p2_i10 |
2311-2314 |
Pharmacological |
denotes |
XKB |
| p1_all16 |
2442-2445 |
Intervention |
denotes |
XKB |
| p2_i11 |
2442-2445 |
Pharmacological |
denotes |
XKB |
| p1_all17 |
2610-2613 |
Intervention |
denotes |
XKB |
| p2_i12 |
2610-2613 |
Pharmacological |
denotes |
XKB |
| p1_all18 |
2687-2690 |
Intervention |
denotes |
XKB |
| p2_i13 |
2687-2690 |
Pharmacological |
denotes |
XKB |
| p2_o18 |
3002-3022 |
Physical |
denotes |
mechanisms of action |
| p1_all19 |
3065-3166 |
Outcome |
denotes |
absorption, distribution, metabolism and excretion [ADME]), and toxicology for most natural products. |
| p2_i14 |
3715-3722 |
Pharmacological |
denotes |
oxidize |
| p2_i15 |
3901-3909 |
Pharmacological |
denotes |
CYP3A4/5 |
| p2_i16 |
4178-4185 |
Pharmacological |
denotes |
digoxin |
| p2_i17 |
4187-4195 |
Pharmacological |
denotes |
warfarin |
| p2_i18 |
4201-4212 |
Pharmacological |
denotes |
carboplatin |
| p2_o26 |
4484-4517 |
Physical |
denotes |
coronary heart disease and stroke |
| p2_o26 |
4543-4548 |
Mortality |
denotes |
death |
| p2_o27 |
4597-4610 |
Mortality |
denotes |
died from CVD |
| p2_o28 |
4696-4702 |
Mortality |
denotes |
deaths |
| p2_o28 |
4756-4762 |
Mortality |
denotes |
deaths |
| p1_all20 |
5726-5769 |
Intervention |
denotes |
Ketoconazole Midazolam
Probucol Xyloketal B |
| p2_i19 |
5726-5769 |
Pharmacological |
denotes |
Ketoconazole Midazolam
Probucol Xyloketal B |
| p2_o38 |
5749-5769 |
Physical |
denotes |
Probucol Xyloketal B |
| p1_all21 |
6638-6688 |
Outcome |
denotes |
Enrichment scores and Fisher's Exact test P-values |
| p2_i20 |
7300-7303 |
Pharmacological |
denotes |
XKB |
| p1_all22 |
7300-7342 |
Intervention |
denotes |
XKB, midazolam, ketoconazole, and probucol |
| p2_i21 |
7305-7314 |
Pharmacological |
denotes |
midazolam |
| p2_i22 |
7316-7328 |
Pharmacological |
denotes |
ketoconazole |
| p2_i23 |
7334-7342 |
Pharmacological |
denotes |
probucol |
| p1_all23 |
7428-7473 |
Outcome |
denotes |
Electrostatic energy and van der Waals forces |
| p1_all24 |
7616-7618 |
Population |
denotes |
28 |
| p2_p0 |
7616-7618 |
Sample-size |
denotes |
28 |
| p2_i24 |
7654-7657 |
Pharmacological |
denotes |
XKB |
| p1_all25 |
7654-7696 |
Intervention |
denotes |
XKB, midazolam, ketoconazole, and probucol |
| p2_i25 |
7659-7668 |
Pharmacological |
denotes |
midazolam |
| p2_i26 |
7670-7682 |
Pharmacological |
denotes |
ketoconazole |
| p2_i27 |
7688-7696 |
Pharmacological |
denotes |
probucol |
| p1_all26 |
7804-7846 |
Intervention |
denotes |
XKB, midazolam, ketoconazole, and probucol |
| p2_i28 |
7809-7818 |
Pharmacological |
denotes |
midazolam |
| p2_i29 |
7820-7832 |
Pharmacological |
denotes |
ketoconazole |
| p2_i30 |
7838-7846 |
Pharmacological |
denotes |
probucol |
| p2_i31 |
7899-7902 |
Pharmacological |
denotes |
XKB |
| p1_all27 |
7899-7941 |
Intervention |
denotes |
XKB, midazolam, ketoconazole, and probucol |
| p2_i32 |
7904-7913 |
Pharmacological |
denotes |
midazolam |
| p2_i33 |
7915-7927 |
Pharmacological |
denotes |
ketoconazole |
| p2_i34 |
7933-7941 |
Pharmacological |
denotes |
probucol |
| p2_i35 |
8334-8337 |
Pharmacological |
denotes |
XKB |
| p1_all28 |
8334-8376 |
Intervention |
denotes |
XKB, midazolam, ketoconazole, and probucol |
| p2_i36 |
8339-8348 |
Pharmacological |
denotes |
midazolam |
| p2_i37 |
8350-8362 |
Pharmacological |
denotes |
ketoconazole |
| p2_i38 |
8368-8376 |
Pharmacological |
denotes |
probucol |
| p1_all29 |
8465-8602 |
Outcome |
denotes |
solubility, absorption, permeability across the blood-brain barrier, interactions with CYP2D6, hepatotoxicity, and plasma protein binding |
| p2_o57 |
8465-8602 |
Physical |
denotes |
solubility, absorption, permeability across the blood-brain barrier, interactions with CYP2D6, hepatotoxicity, and plasma protein binding |
